Madagascar

Population 2018  26 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>61 (40–87)</td>
<td>233 (151–333)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.96 (0.61–1.4)</td>
<td>3.6 (2.3–5.2)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>0.43 (0.082–1.1)</td>
<td>1.6 (0.31–4)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>13 (7.5–19)</td>
<td>48 (28–73)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.38 (0.24–0.54)</td>
<td>1.4 (0.92–2.1)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- % tested with rapid diagnostics at time of diagnosis
- % with known HIV status
- % pulmonary
- % bacteriologically confirmed***
- % children aged 0-14 years
- % women
- % men

TB case notifications, 2018

- Total new and relapse 33 786
- % tested with rapid diagnostics at time of diagnosis
- % with known HIV status 64%
- % pulmonary 79%
- % bacteriologically confirmed*** 86%
- % children aged 0-14 years 7%
- % women 37%
- % men 56%

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018 55% (39–85)
- TB patients facing catastrophic total costs
- TB case fatality ratio (estimated mortality/estimated incidence), 2018 22% (11–36)

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance***
  - New cases 0%
  - Previously treated cases 50%

Laboratory-confirmed cases*

- MDR/RR-TB: 22, XDR-TB: 0

Notified cases by age group and sex, 2018

Females  
Males

Incidence

0-4  
05-14  
15-24  
25-34  
35-44  
45-54  
55-64  
65+

0  
2500  
5000  
7500

Treatment success rate and cohort size

<table>
<thead>
<tr>
<th></th>
<th>Success</th>
<th>Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>New cases registered in 2017</td>
<td>64%</td>
<td>29 654</td>
</tr>
<tr>
<td>Previously treated cases registered in 2017</td>
<td>76%</td>
<td>2 331</td>
</tr>
<tr>
<td>MDR/RR-TB cases started on second-line treatment in 2016</td>
<td>60%</td>
<td>15</td>
</tr>
</tbody>
</table>

Treatment success rate and cohort size

<table>
<thead>
<tr>
<th></th>
<th>Success</th>
<th>Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>New cases registered in 2017</td>
<td>64%</td>
<td>29 654</td>
</tr>
<tr>
<td>Previously treated cases registered in 2017</td>
<td>76%</td>
<td>2 331</td>
</tr>
<tr>
<td>MDR/RR-TB cases started on second-line treatment in 2016</td>
<td>60%</td>
<td>15</td>
</tr>
</tbody>
</table>

TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

34% (31–38)

TB financing, 2019

- National TB budget (US$ millions) 2.9
- Funding source: 0% domestic, 100% international, 0% unfunded

Ranges represent uncertainty intervals

MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

Calculated for pulmonary cases only

Includes cases with unknown previous TB treatment history

Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-02-12

Data: www.who.int/tb/data